Anti-Obesity Prescription Drugs Market report provides the latest market data along with industry future trends, which keeps tracking of users driving revenue growth rate of Anti-Obesity Prescription Drugs Market by drug class (orlistat, phentermine and topiramate, bupropion and naltrexone, lorcaserin, liraglutide), distribution channel (retail pharmacy, hospital pharmacy and online pharmacy), age group (pediatric and adult) market status and outlook of global and major regions, from manufacturers, and end industries. As this report is expected to help key players among the Anti-Obesity Prescription Drugs Market it includes the five years Industry analysis and the 6 years annual forecast from 2018 to 2024. Some of the prominent participants in the Global Anti-Obesity Prescription Drugs Market are F Hoffmann La Roche Ltd, Orexigen Therapeutics, Inc, Novo Nordisk A/S, Arena Pharmaceuticals, Inc, GlaxoSmithKline, VIVUS, Inc, BoehringerIngelheim, Alizyme and Others. According to the report the Global Anti-Obesity Prescription Drugs Market is projected to grow at a CAGR of 4.97% in terms of value over the period of 2018-2024.
Unhealthy Food which is Rich in Cholesterol has increased which Leads to a Rise in Demand for Anti-Obesity Prescription Drugs
The pharmacological agents that helps to reduce or control weight. Anti-obesity drugs help in reducing body mass either by reducing the hunger or increasing the consumption of calories. The ingesting of unhealthy food which is rich in cholesterol has increased which leads to a rise in demand for anti-obesity prescription drugs. Rising level of chronic stress also contributes towards obesity. Rising consumption of alcoholic beverages and unhealthy food which is rich in cholesterol that leads to obesity is driving the growth of the market.
Obesity Management is expected to Impact Growth of the Global Anti-Obesity Prescription Drugs Market Positively
Growing occurrence of depression has led to growing consumption of the psychotropic drugs; the side effect of this drug is increasing which result to obesity. Moreover, increasing incidences of diabetes have surged up the consumption of medications. These medications have appetite stimulating features, due to which the patients incline to eat more. Eating disorders due to antidepressants and diabetic drugs increase the diet which has sustained to contribute towards obesity. Growing demand for obesity management is expected to impact growth of the global anti-obesity prescription drugs market positively.
The report on global anti-obesity prescription drugs market covers segments such as, drug class, distribution channel and age group. On the basis of drug class the global anti-obesity prescription drugs market is categorized into orlistat, phentermine and topiramate, bupropion and naltrexone, lorcaserin and liraglutide. On the basis of distribution channel the global anti-obesity prescription drugs market is categorized into retail pharmacy, hospital pharmacy and online pharmacy. On the basis of age group the global anti-obesity prescription drugs market is categorized into pediatric and adult.
Click the Below Full Report Link: https://www.infiniumglobalresearch.com/healthcare_medical_devices/global_anti-obesity_prescription_drugs_market